title: [Effects of levonorgestrel intrauterine system on the expressions of estrogen receptor, progesterone receptor and insulin-like growth factor-1].
abstract: OBJECTIVE
  To explore the effects of levonorgestrel intrauterine system on estrogen receptor (ER) and progesterone receptor (PR), insulin-like growth factor-1 (IGF-1) of endometrial polyps and surrounding endometrial tissue.
  
  
  METHODS
  A total of 250 cases of hysteroscopic resection for endometrial polyps were divided into study group (n = 125) with placement of levonorgestrel intrauterine system after hysteroscopic electroresection and control group (n = 125) without placement. The intraoperative and postoperative expressions of ER, PR and IGF-1 in endometrial biopsy specimens were measured by immunohistochemistry. They were followed up for 2 years to analyze the recurrence of endometrial polyp.
  
  
  RESULTS
  All patients had successful surgery. When intraoperative and postoperative specimens were compared with regards to the expressions of ER, PR and IGF-1, significant differences existed between two groups. During a 2-year follow-up, the recurrence of endometrial polyp was 10.89% in control group versus 0 in study group.
  
  
  CONCLUSIONS
  Levonorgestrel intrauterine system may inhibit the recurrence and formation of endometrial polyp through lowering the expressions of ER, PR and IGF-1.
authors.affiliation: Maternal & Children Health Hospital, Jiaxing 314051, China.
authors.forename: Xiaojie
authors.initials: X
authors.lastname: Wu
authors.affiliation: Maternal & Children Health Hospital, Jiaxing 314051, China.
authors.forename: Xia
authors.initials: X
authors.lastname: Liu
authors.affiliation: Maternal & Children Health Hospital, Jiaxing 314051, China.
authors.forename: Xiaoying
authors.initials: X
authors.lastname: Jin
authors.affiliation: Maternal & Children Health Hospital, Jiaxing 314051, China. Email: 664212960@qq.com.
authors.forename: Xingyun
authors.initials: X
authors.lastname: Xu
mesh_terms: D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007334:Insulin-Like Growth Factor I; D007436:Intrauterine Devices, Medicated; D016912:Levonorgestrel / Q000627:therapeutic use*; D009364:Neoplasm Recurrence, Local; D011127:Polyps; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D013002:Somatomedins; D014594:Uterine Neoplasms
chemical_list: D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D013002:Somatomedins; D016912:Levonorgestrel; D007334:Insulin-Like Growth Factor I